Abstract
The cullin-RING E3 ligases (CRLs) are the biggest components of the E3 ubiquitin ligase protein family, and they represent an essential role in various diseases that occur because of abnormal activation, particularly in tumors development. Regulation of CRLs needs neddylation, a post-translational modification involving an enzymatic cascade that transfers small, ubiquitin-like NEDD8 protein to CRLs. Many previous studies have confirmed neddylation as an enticing target for anticancer drug discoveries, and few recent studies have also found a significant increase in advancement in protein neddylation, including preclinical and clinical target validation to discover the neddylation inhibitor compound. In the present review, we first presented briefly the essence of CRLs' neddylation and its control, systematic analysis of CRLs, followed by the description of a few recorded chemical inhibitors of CRLs neddylation enzymes with recent examples of preclinical and clinical targets. We have also listed various structure-based pointing of protein–protein dealings in the CRLs' neddylation reaction, and last, the methods available to discover new inhibitors of neddylation are elaborated. This review will offer a concentrated, up-to-date, and detailed description of the discovery of neddylation inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
An H, Statsyuk AV (2013) An inhibitor of ubiquitin conjugation and aggresome formation. Chem Sci 6(9):5235–5245. https://doi.org/10.1039/c5sc01351h
Aubry A, Yu T, Bremner R (2020) Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy. Cell Death Disco 6(1):1–12. https://doi.org/10.1038/s41420-020-0237-8
Baek K, Krist DT, Prabu JR et al (2020) NEDD8 nucleates a multivalent cullin–RING–UBE2D ubiquitin ligation assembly. Nature 578(7795):461–466. https://doi.org/10.1038/s41586-020-2000-y
Baek K, Scott DC, Schulman BA (2021) NEDD8 and ubiquitin ligation by cullin-RING E3 ligases. Curr Opin Struct Biol 67:101–109. https://doi.org/10.1016/j.sbi.2020.10.007
Barghout SH, Schimmer AD (2021) E1 enzymes as therapeutic targets in cancer. Pharmacol Rev 73(1):1–56. https://doi.org/10.1124/pharmrev.120.000053
Bi Y, Cui D, Xiong X, Zhao Y (2020) The characteristics and roles of β-TrCP1/2 in carcinogenesis. FEBS J. https://doi.org/10.1111/febs.15585
Bradford BR, Jin C (2021) Stem-loop binding protein and metal carcinogenesis. Seminars in cancer biology, vol 76. Academic Press, New York, pp 38–44. https://doi.org/10.1021/cb500860x
Buckley DL, Crews CM (2014) Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed 53(9):2312–2330. https://doi.org/10.1002/anie.201307761
Busche S, John K, Wandrer F, Vondran FW, Lehmann U, Wedemeyer H et al (2021) BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death Dis 12:736. https://doi.org/10.1038/s41419-021-04020-z
Cai Z, Moten A, Peng D, Hsu CC, Pan BS et al (2020) The Skp2 pathway: a critical target for cancer therapy. Seminars in cancer biology, vol 67. Academic Press, New York, pp 16–33. https://doi.org/10.1016/j.semcancer.2020.01.013
Chang L, Ruiz P, Ito T, Sellers WR (2021) Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell 39(4):466–479. https://doi.org/10.1016/j.ccell.2020.12.008
Che X, Jian F, Wang Y et al (2020) FBXO2 promotes proliferation of endometrial cancer by ubiquitin-mediated degradation of FBN1 in the regulation of the cell cycle and the autophagy pathway. Front Cell Dev Biol 8:843. https://doi.org/10.3389/fcell.2020.00843
Chen JJ, Tsu CA, Gavin JM et al (2011) Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. J Biol Chem 286(47):40867–40877. https://doi.org/10.1074/jbc.M111.279984
Chen L, Liu S, Tao Y (2020) Regulating tumor suppressor genes: post-translational modifications. Sig Transduct Target Ther 5:1–25. https://doi.org/10.1038/s41392-020-0196-9
Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE, Vucic D (2021) Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ 28(2):591–605. https://doi.org/10.1038/s41418-020-00708-5
Cordo JC, Zwet KCB, Rob Pieters JP (2021) T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies. Blood Cancer Discov 2(1):19. https://doi.org/10.1158/2643-3230.BCD-20-0093
Cote K, Lalla EA, Konstantinidis M, Daly M, Dietrich P (2019) A combined Raman, LIF, and micro-LIBS system with time-resolved fluorescence capabilities for planetary exploration applications. In: Proceedings of the International Astronautical Congress, IAC, International Astronautical Federation, IAF
Dadashpour S, Emami S (2018) Indole in the target-based design of anticancer agents: a versatile scaffold with diverse mechanisms. Eur J Med Chem 150:9–29. https://doi.org/10.1016/j.ejmech.2018.02.065
Das PK, Islam F, Lam AK (2020) The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells 9(6):1392. https://doi.org/10.3390/cells9061392
de Esch IJ, Erlanson DA, Jahnke W, Johnson CN, Walsh L (2021) Fragment-to-lead medicinal chemistry publications in 2020. J Med Chem. https://doi.org/10.1021/acs.jmedchem.1c01803
Du MG, Peng ZQ, Gai WB, Liu F, Liu W, Chen YJ et al (2021) The absence of PTEN in breast cancer is a driver of MLN4924 resistance. Front Cell Dev Biol 9:667435. https://doi.org/10.3389/fcell.2021.667435
Elcheva IA, Spiegelman VS (2021) Targeting RNA-binding proteins in acute and chronic leukemia. Leukemia 35(2):360–376. https://doi.org/10.1038/s41375-020-01066-4
Emami-Nemini A, Roux T, Leblay M, Bourrier E, Lamarque L, Trinquet E, Lohse MJ (2013) Time-resolved fluorescence ligand binding for G protein-coupled receptors. Nat Protoc 8(7):1307–1320. https://doi.org/10.1038/nprot.2013.073
Enchev RI, Schulman BA, Peter M (2015) Protein neddylation: beyond cullin–RING ligases. Nat Rev Mol Cell Biol 16:30–44. https://doi.org/10.1038/nrm3919
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: an overview. Int J Cancer Res 149:778–789. https://doi.org/10.1002/ijc.33588
Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM (2021) The anti-tumor activity of the NEDD8 inhibitor pevonedistat in neuroblastoma. Int J Mol Sci 22:6565. https://doi.org/10.3390/ijms22126565
Gai W, Peng Z, Liu CH, Zhang L, Jiang H (2021) Advances in cancer treatment by targeting the neddylation pathway. Front Cell Dev Biol 9:719. https://doi.org/10.3389/fcell.2021.653882
Gatti V, Bernassola F, Talora C, Melino G, Peschiaroli A (2020) The impact of the ubiquitin system in the pathogenesis of squamous cell carcinomas. Cancers 12(6):1595. https://doi.org/10.3390/cancers12061595
Hammill JT, Scott DC, Min J et al (2018) Piperidinyl ureas chemically control defective in cullin neddylation 1 (DCN1)-mediated cullin neddylation. J Med Chem 61(7):2680–2693. https://doi.org/10.1021/acs.jmedchem.7b01277
Handy DE, Castro R, Loscalzo J (2011) Epigenetic modifications. Circulation 123(19):2145–2156. https://doi.org/10.1161/CIRCULATIONAHA.110.956839
Hassanpour SH, Dehghani M (2017) Review of cancer from perspective of molecular. J Cancer Res Pract 4(4):127–129. https://doi.org/10.1016/j.jcrpr.2017.07.001
He X, Zhu A, Feng J, Wang X (2021) Role of neddylation in neurological development and diseases. Biotechnol Appl Biochem. https://doi.org/10.1002/bab.2112
Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH (2020) Protein-based nanoparticles as drug delivery systems. Pharmaceutics 12(7):604. https://doi.org/10.3390/pharmaceutics12070604
Horn-Ghetko D, Krist DT, Prabu JR et al (2021) Ubiquitin ligation to F-box protein targets by SCF–RBR E3–E3 super-assembly. Nature 590:671–676. https://doi.org/10.1038/s41586-021-03197-9
Houck KA, Kavlock RJ (2008) Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol Appl Pharmacol 227(2):163–178. https://doi.org/10.1016/j.taap.2007.10.22
Hryniewicz-Jankowska A, Wierzbicki J, Tabola R, Stach K, Sossey-Alaoui K, Augoff K (2021) Article the effect of neddylation inhibition on inflammation-induced mmp9 gene expression in esophageal squamous cell carcinoma. Int J Mol Sci 22(4):1–17. https://doi.org/10.3390/ijms22041716
Hyer ML, Milhollen MA, Ciavarri J et al (2018) A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med 24:186–193. https://doi.org/10.1038/nm.4474
Islam Z, Ali AM, Naik A, Eldaw M, Decock J, Kolatkar PR (2021) Transcription factors: the fulcrum between cell development and carcinogenesis. Front Oncol 11:681377. https://doi.org/10.3389/fonc.2021.681377
Jang SM, Redon CE, Thakur BL, Bahta MK, Aladjem MI (2020) Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases. Exp Mol Med 52(10):1637–1651. https://doi.org/10.1038/s12276-020-00508-4
Jevtić P, Haakonsen DL, Rapé M (2021) An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chem Biol 28(7):1000–1013. https://doi.org/10.1016/j.chembiol.2021.04.002
Keuss MJ, Thomas Y, Mcarthur R, Wood NT, Knebel A, Kurz T (2016) Characterization of the mammalian family of DCN-type NEDD8 E3 ligases. J Cell Sci 129(7):1441–1454. https://doi.org/10.1242/jcs.181784
Kim JH, Jung JH, Lee HJ, Sim DY, Im E, Park J et al (2021a) UBE2M drives hepatocellular cancer progression as a p53 negative regulator by binding to MDM2 and ribosomal protein L11. Cancers 13(19):4901. https://doi.org/10.3390/cancers13194901
Kim SO, Cho KS, Kim BY, Lee KH (2021b) Cullin 1 (CUL1) promotes primary ciliogenesis through the induction of ubiquitin-proteasome-dependent Dvl2 degradation. Int J Mol Sci 22(14):7572. https://doi.org/10.3390/ijms22147572
Kobayashi A, Kang M-I, Okawa H et al (2004) Oxidative stress sensor keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24(16):7130–7139. https://doi.org/10.1128/mcb.24.16.7130-7139.2004
Kordbacheh S, Kasko AM (2021) Peptide and protein engineering by modification of backbone and sidechain functional groups. Polym Int 70(7):889–896. https://doi.org/10.1002/pi.6208
LaPlante G, Zhang W (2021) Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors. Cancers 13(12):3079. https://doi.org/10.3390/cancers13123079
Li J, Zou J, Littlejohn R, Liu J, Su H (2020) Neddylation, an emerging mechanism regulating cardiac development and function. Front Physiol 11:1624. https://doi.org/10.3389/fphys.2020.612927
Li Y, Wang C, Xu T, Pan P, Yu Q, Xu L et al (2021a) Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy. Acta Pharm Sin B 11(11):3567–3584. https://doi.org/10.1016/j.apsb.2021.07.012
Li Z, Hu N, Dai L, Hou X, Hu W, Liang W, Wang X (2021b) Cullin-5 (CUL5) as a potential prognostic marker in a pan-cancer analysis of human tumors. Bioengineered 12(1):5348–5360. https://doi.org/10.1080/21655979.2021.1940042
Liu L, Lee S, Zhang J et al (2009) CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell 34(4):451–460. https://doi.org/10.1016/j.molcel.2009.04.020
Liu Y, Mao C, Wang M, Liu N, Ouyang L, Liu S et al (2020) Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene 39(11):2358–2376. https://doi.org/10.1038/s41388-019-1151-5
Lu P, Liu X, Yuan X et al (2016) Discovery of a novel NEDD8 activating enzyme inhibitor with piperidin-4-amine scaffold by structure-based virtual screening. ACS Chem Biol 11(7):1901–1907. https://doi.org/10.1021/acschembio.6b00159
Lucendo E, Sancho M, Lolicato F, Javanainen M, Kulig W, Leiva D et al (2020) Mcl-1 and Bok transmembrane domains: unexpected players in the modulation of apoptosis. PNAS 117(45):27980–27988. https://doi.org/10.1073/pnas.2008885117
Maneiro M, De Vita E, Conole D, Kounde CS, Zhang Q, Tate EW (2021) PROTACs, molecular glues and bifunctionals from bench to bedside: unlocking the clinical potential of catalytic drugs. Progress in medicinal chemistry, vol 60. Elsevier, Amsterdam, pp 67–190. https://doi.org/10.1016/bs.pmch.2021.01.002
Milhollen MA, Traore T, Adams-Duffy J et al (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood 116(9):1515–1523. https://doi.org/10.1182/blood-2010-03-272567
Misra M, Kuhn M, Löbel M, An H, Statsyuk AV, Sotriffer C, Schindelin H (2017) Dissecting the specificity of adenosyl sulfamate inhibitors targeting the ubiquitin-activating enzyme. Structure 25(7):1120–1129. https://doi.org/10.1016/j.str.2017.05.001
Mo Z, Zhang Q, Liu Z, Lauer J, Shi Y, Sun L et al (2016) Neddylation requires glycyl-tRNA synthetase to protect activated E2. Nat Struct Mol Biol 23:730–737. https://doi.org/10.1038/nsmb.3250
Muraoka H, Yoshimura C, Kawabata R, Tsuji S, Hashimoto A, Ochiiwa H et al (2019) Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways. Cancer Sci 110(12):3802–3810. https://doi.org/10.1111/cas.14209
Newton K, Matsumoto ML, Wertz IE et al (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134(4):668–678. https://doi.org/10.1016/j.cell.2008.07.039
Ni S, Chen X, Yu Q et al (2020) Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth. Eur J Med Chem 185:111848. https://doi.org/10.1016/j.ejmech.2019.111848
Ochiiwa H, Ailiken G, Yokoyama M et al (2021) TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia. Oncogene 40(7):1217–1230. https://doi.org/10.1038/s41388-020-01586-4
Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T (2016) The role of cullin 5-containing ubiquitin ligases. Cell Div 11(1):1–16. https://doi.org/10.1186/s13008-016-0016-3
Paccosi E, Proietti-De-Santis L (2021) The emerging role of Cockayne group A and B proteins in ubiquitin/proteasome-directed protein degradation. Mech Ageing Dev 195:111466. https://doi.org/10.1016/j.mad.2021.111466
Papatheofani V, Levidou G, Sarantis P, Koustas E, Karamouzis MV, Pergaris A et al (2021) HuR protein in hepatocellular carcinoma: implications in development, prognosis and treatment. Biomedicines 9(2):119. https://doi.org/10.3390/biomedicines9020119
Park J, Cho J, Song EJ (2020) Ubiquitin–proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res 43:1144–1161. https://doi.org/10.1007/s12272-020-
Pillaiyar T, Meenakshisundaram S, Manickam M, Sankaranarayanan M (2020) A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery. Eur J Med Chem 195:112275. https://doi.org/10.1016/j.ejmech.2020.112275
Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X, Zheng L (2020) RNA-binding proteins in tumor progression. J Hematol Oncol 13:90. https://doi.org/10.1186/s13045-020-00927-w
Qiu Y, Li X, He X, Pu J, Zhang J, Lu S (2020) Computational methods-guided design of modulators targeting protein–protein interactions (PPIs). Eur J Med Chem 207:112764. https://doi.org/10.1016/j.ejmech.2020.112764
Ramachandran S, Ciulli A (2021) Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues. Curr Opin Struct Biol 67:110–119. https://doi.org/10.1016/j.sbi.2020.10.009
Rambacher KM, Calabrese MF, Yamaguchi M (2021) Perspectives on the development of first-in-class protein degraders. Future Med Chem 13(14):1203–1226. https://doi.org/10.4155/fmc-2021-0033
Rica E, Álvarez S, Serratosa F (2021) Ligand-based virtual screening based on the graph edit distance. Int J Mol Sci 22(23):12751. https://doi.org/10.3390/ijms222312751
Romasanta AK, van der Sijde P, de Esch IJ (2021) Absorbing knowledge from an emerging field: the role of interfacing by proponents in big pharma. Technovation. https://doi.org/10.1016/j.technovation.2021.102363
Ross AB, Langer JD, Jovanovic M (2021) Proteome turnover in the spotlight: approaches, applications, and perspectives. Mol Cell Proteomics 20:100016. https://doi.org/10.1074/mcp.R120.002190
Russo GL, Stampone E, Cervellera C, Borriello A (2020) Regulation of p27Kip1 and p57Kip2 functions by natural polyphenols. Biomolecules 10(9):1316. https://doi.org/10.3390/biom10091316
Santonico E (2019) New insights into the mechanisms underlying NEDD8 structural and functional specificities. Ubiquitin Proteasome Syst Curr Insights into Mech Cell Regul Dis. https://doi.org/10.5772/intechopen.83426
Schabla NM, Mondal K, Swanson PC (2019) DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor. J Mol Cell Biol 11(9):725–735. https://doi.org/10.1093/jmcb/mjy085
Scholz N, Kurian KM, Siebzehnrubl FA, Licchesi JD (2020) Targeting the ubiquitin system in glioblastoma. Front Oncol 10:574011. https://doi.org/10.3389/fonc.2020.574011
Schrock MS, Stromberg BR, Scarberry L, Summers MK (2020) APC/C ubiquitin ligase: functions and mechanisms in tumorigenesis. Semin Cancer Biol 67:80–91. https://doi.org/10.1016/j.semcancer.2020.03.001
Schulman BA, Harper JW (2009) Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 10:319–331. https://doi.org/10.1038/nrm2673
Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF et al (2021) Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 35:2119–2124. https://doi.org/10.1038/s41375-021-01125-4
Shah R, Chen S (2020) Metabolic signaling cascades prompted by glutaminolysis in cancer. Cancers (basel) 12(9):1–16. https://doi.org/10.3390/cancers12092624
Sharma P, Nag A (2014) CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol. https://doi.org/10.1098/rsob.130217
Shi CS, Kuo KL, Lin WC, Chen MS, Liu SH, Liao SM et al (2020) Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study. Am J Cancer Res 10(3):953–964 (PMC7136913)
Skaar J, Pagan J, Pagano M (2014) SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov 13:889–903. https://doi.org/10.1038/nrd4432
Soucy TA, Smith PG, Milhollen MA et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458(7239):732–736. https://doi.org/10.1038/nature07884
Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE (2010) The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1(7):708–716. https://doi.org/10.1177/1947601910382898
Stuber K, Schneider T, Werner J, Kovermann M, Marx A, Scheffner M (2021) Structural and functional consequences of NEDD8 phosphorylation. Nat Commun 12:5939. https://doi.org/10.1038/s41467-021-26189-9
Su L, Bryan N, Battista S, Freitas J, Garabedian A, D’Alessio F et al (2020) Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep 10(1):1–14. https://doi.org/10.1038/s41598-020-75890-0
Sun T, Liu Z, Yang Q (2020a) The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer 19(1):1–19. https://doi.org/10.1186/s12943-020-01262-x
Sun Z, Jiang Q, Li J, Guo J (2020b) The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Sig Transduct Target Ther 5:150. https://doi.org/10.1038/s41392-020-00265-w
Sweeney MA, Iakova P, Maneix L et al (2020) The ubiquitin ligase Cullin-1 associates with chromatin and regulates transcription of specific c-MYC target genes. Sci Rep 10(1):1–12. https://doi.org/10.1038/s41598-020-70610-0
Swords RT, Coutre S, Maris MB et al (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131(13):1415–1424. https://doi.org/10.1182/blood-2017-09-805895
Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT (2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 15(3):253–264. https://doi.org/10.1517/14728222.2011.550877
Wang K, Reichermeier KM, Liu X (2021a) Quantitative analyses for effects of neddylation on CRL2VHL substrate ubiquitination and degradation. Protein Sci 30(11):2338–2345. https://doi.org/10.1002/pro.4176
Wang X, Best S, Danilov AV (2021b) Neddylation and anti-tumor immunity. Oncotarget 12(21):2227. https://doi.org/10.18632/oncotarget.28019
Watson IR, Irwin MS, Ohh M (2011) NEDD8 pathways in cancer, Sine Quibus Non. Cancer Cell 19(2):168–176. https://doi.org/10.1016/j.ccr.2011.01.002
Weitzel KM (2011) Bond-dissociation energies of cations—pushing the limits to quantum state resolution. Mass Spectrom Rev 30(2):221–235. https://doi.org/10.1002/mas.20276
Wen J, Wang D (2021) Deciphering the PTM codes of the tumor suppressor p53. J Mol Cell Biol 13(11):774–785. https://doi.org/10.1093/jmcb/mjab047
Wu P, Oren O, Gertz MA et al (2020) Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep 22:66. https://doi.org/10.1007/s11912-020-00931-w
Yang J, An HW, Wang H (2021) Self-assembled peptide drug delivery systems. ACS Appl Bio Mater 4(1):24–46. https://doi.org/10.1021/acsabm.0c00707
Yang K, Wu H, Zhang Z, Leisten ED, Nie X et al (2020) Development of selective histone deacetylase 6 (HDAC6) degraders recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. ACS Med Chem Lett 11(4):575–581. https://doi.org/10.1021/acsmedchemlett.0c00046
Yoshimura C, Muraoka H, Ochiiwa H et al (2019) TAS4464, a highly potent and selective inhibitor of NEDD8-activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models. Mol Cancer Ther 18(7):1205–1216. https://doi.org/10.1158/1535-7163.MCT-18-0644
Yu Q, Hu Z, Shen Y, Jiang Y, Pan P et al (2020) Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes. Neoplasia 22(4):179–191. https://doi.org/10.1016/j.neo.2020.02.003
Zhang S, Tan J, Lai Z et al (2014) Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-activating enzyme inhibitors. J Chem Inf Model 54(6):1785–1797. https://doi.org/10.1021/ci5002058
Zhang X, Linder S, Bazzaro M (2020) Drug development targeting the ubiquitin–proteasome system (UPS) for the treatment of human cancers. Cancers 12(4):902. https://doi.org/10.3390/cancers12040902
Zhao Y, Morgan MA, Sun Y (2014) Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal 21(17):2383–2400. https://doi.org/10.1089/ars.2013.5795
Zhao J, Lan W, Peng J, Guan B, Liu J, et al (2021) Babao dan reverses multiple-drug resistance in gastric cancer cells via triggering apoptosis and autophagy and inhibiting PI3K/AKT/mTOR signaling. Evid-Based Complementary Altern Med 5631942. https://doi.org/10.1155/2021/5631942
Zheng S, Tao W (2020) Targeting Cullin-RING E3 ligases for radiosensitization: from NEDDylation inhibition to PROTACs. Front Oncol 10:1517. https://doi.org/10.3389/fonc.2020.01517
Zhong HJ, Liu LJ, Chan DSH, Wang HM, Chan PWH, Ma DL, Leung CH (2014) Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme. Biochimie 102:211–215. https://doi.org/10.1016/j.biochi.2014.03.005
Zhong HJ, Ma VPY, Cheng Z, Chan DSH, He HZ et al (2012) Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. Biochimie 94(11):2457–2460. https://doi.org/10.1016/j.biochi.2012.06.004
Zhou L, Jiang Y, Liu X et al (2019) Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer. Oncogene 38(29):5792–5804. https://doi.org/10.1038/s41388-019-0840-4
Zhou Q, Zheng Y, Sun Y (2021) Neddylation regulation of mitochondrial structure and functions. Cell Biosci 11:55. https://doi.org/10.1186/s13578-021-00569-6
Zou T, Zhang J (2021) Diverse and pivotal roles of neddylation in metabolism and immunity. FEBS J 288(13):3884–3912. https://doi.org/10.1111/febs.15584
Funding
This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
IB, LG, MM, MZ, HS and MK delineated and conducted the literature survey. All listed authors wrote, read, and approved the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest could be perceived as prejudicial to the impartiality of the reported research.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Bano, I., Malhi, M., Zhao, M. et al. A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy. 3 Biotech 12, 103 (2022). https://doi.org/10.1007/s13205-022-03162-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-022-03162-x